Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRC for Autoimmune Refractory Epilepsy
NCT03676569Phase 1Completed
- Sponsor
- Mossakowski Medical Research Institute
- Start
- Nov 2015
- Primary completion
- Apr 2019
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived stem/stromal cells in autoimmune epilepsy, sponsored by Mossakowski Medical Research Institute. Primary endpoint: Rate of epileptic seizures at 3 months. Started Nov 2015; status: completed.
02
Drugs
autologous adipose-derived stem/stromal cells
03
Conditions
autoimmune epilepsy
Beyond the preview
Go deeper on NCT03676569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676569.